相关实验视频
Updated: May 5, 2026
10:36
A Swine Model of Neonatal Asphyxia
Published on: October 11, 2011
14.3K
早期的水皮质与安慰剂在新生儿休克 - - 双盲随机对照试验
Sankalp Dudeja1, Shiv Sajan Saini2, Venkataseshan Sundaram1
1Division of Neonatology, Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
概括
早期的皮并没有显著降低患有抗流体冲击的新生儿14天死亡率. 这项研究在重症新生儿中比较了皮和安慰剂,发现两组之间的结果相似.
科学领域:
- 新生儿重症监护中心
- 儿科重症监护医学 儿科重症监护医学
- 新生儿药理学 在新生儿中
背景情况:
- 新生儿的耐液体冲击是一个关键的情况,需要及时管理.
- 血管活性疗法是标准的,但它的有效性可能有限.
- 早期皮在新生儿休克中的作用仍然是研究领域.
研究的目的:
- 为了评估与安慰剂相比早期皮松剂的有效性,以减少患有抗流体冲击的新生儿14天全因死亡率.
- 评估早期皮对血管活性药物支持的持续时间和其他临床结果的影响.
主要方法:
- 采用了一种随机对照试验设计.
- 患有抗流体冲击的新生儿在早期接受过皮质或液安慰剂,除了血管活性药物外.
- 参与者被监测了14天的全因死亡率和其他临床终点.
主要成果:
- 84名新生儿被随机分类,其中43名在早期的皮组和41名在安慰剂组.
- 在早期皮和安慰剂组之间,14天全因死亡率没有显著差异 (OR 0.53;95% CI 0.19,1.52).
- 两组都显示了类似的血管活性药物使用持续时间,血管活性-异位素得分,以及不良反应和中期并发症的发生率.
结论:
- 与血管活性疗法一起早期启动皮并没有显著降低患有抗流体冲击的新生儿14天死亡率.
- 这些发现表明,目前的证据不支持对这种特定的新生儿群体进行早期皮的常规使用.
- 可能需要进一步的研究来确定新生儿的子组,这些新生儿可能会在休克状态下受益于皮质素治疗.
相关概念视频
02:07Blind Procedures
10.8K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.8K
01:11Blinding
2.9K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.9K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703
01:29Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K